A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAB5553A in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2017
At a glance
- Drugs Lesofavumab (Primary)
- Indications Influenza B virus infections
- Focus Adverse reactions
- Sponsors Genentech
- 01 Aug 2017 Results published in the Antimicrobial Agents and Chemotherapy
- 14 Apr 2016 Status changed from recruiting to completed.
- 22 Oct 2015 Status changed from not yet recruiting to recruiting, according to Roche pipeline.